Nutra Pharma Corp. NPHC Archives

WednesdayDec 30, 2015 10:49 am

Nutra Pharma Corporation (NPHC) CEO Publishes Letter to Shareholders

Earlier today, Nutra Pharma Corporation (OTCQB: NPHC), the company behind innovative pharmaceutical products such as Nyloxin® and Pet Pain-Away, released a letter to shareholders. In the letter, Rik J. Deitsch, the company’s chief executive officer, gave investors a brief overview of Nutra Pharma’s progress during 2015, as well as its goals and expectations for the coming months. “We have had a very busy year at Nutra Pharma,” Deitsch explained in the news release. “2015 has been an inflection year for the company, launching our first new product in over two years (Pet Pain-Away), allowing us to begin to get back…

TuesdayDec 29, 2015 5:17 pm

Nutra Pharma Corp. (NPHC) is Doing Things Differently in the Biotech Industry

Nutra Pharma Corp. (OTCQB: NPHC) is introducing new healthcare solutions to the globe. Through ReceptoPharm, a subsidiary, Nutra Pharma is discovering, researching and developing biopharmaceutical products to prevent and/or treat multiple sclerosis (MS), HIV/AIDS, adrenomyeloneuropathy (ADM), herpes, rheumatoid arthritis and pain. Drug Discovery & Development Nutra Pharma is in the business of acquiring, licensing and commercializing pharmaceutical products and technologies, along with homeopathic and ethical drugs for managing pain and neurological disorders, autoimmune and infectious diseases and cancer. The company has several pipeline products both in the market and under research and development. Within the over-the-counter pain management market, Nutra…

FridayDec 18, 2015 10:03 am

Nutra Pharma Corporation (NPHC) Targeting Underserved Pharmaceutical Indications with Proprietary Therapeutic Protein Products

Nutra Pharma Corporation (OTC: NPHC) is a biotechnology company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. The company’s product portfolio includes Cobroxin, the first over-the-counter pain reliever clinically proven to treat moderate to severe chronic pain, and Nyloxin, the only non-narcotic and non-addictive treatment for severe pain. Both products were developed by Nutra Pharma’s wholly-owned drug discovery subsidiary, ReceptoPharm. Currently, ReceptoPharm is developing proprietary therapeutic protein products for the prevention and treatment of viral and neurological diseases by leveraging the specialized receptor-binding proteins found…

WednesdayDec 16, 2015 2:13 pm

Nutra Pharma Corp. (NPHC) CEO Featured in Exclusive QualityStocks Interview

QualityStocks today announces the availability of a new audio interview with Rik Deitsch, CEO of Nutra Pharma Corp. (OTC: NPHC), a biotech company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases. The interview can be heard at http://www.QualityStocks.net/interview-nphc.php. Nutra Pharma is developing a broad product platform for numerous indications, and it currently has 21 patents in its intellectual property portfolio. The QualityStocks interview begins with Deitsch describing Nutra Pharma's business model and three key patents: one for autoimmune disease, one for antiviral therapeutics, and one…

MondayDec 14, 2015 10:32 am

Nutra Pharma Corp. (NPHC) Engages QualityStocks Corporate Communications Suite

Nutra Pharma Corp., a biopharmaceutical company engaged in the acquisition, licensing and marketing of homeopathic treatments and ethical drugs for the management of pain, neurological disorders, cancer, auto-immune and infectious diseases, today announces that it has engaged the Corporate Communications Services of QualityStocks. Based in Scottsdale, Arizona, QualityStocks has assisted more than 300 public companies with their efforts to broaden influence, attract growth capital and improve shareholder value over the past 9 years and 11 months. "We are pleased to have engaged the services of QualityStocks and look forward to a long and fruitful relationship with them as we work…

WednesdayDec 09, 2015 10:03 am

Nutra Pharma Corp. (NPHC) Applies for Additional Orphan Drug Designation for RPI-78M

Nutra Pharma Corp., a biotechnology company marketing Nyloxin® and Pet Pain-Away in the over-the-counter (OTC) pain management market, as well as developing treatments for multiple sclerosis (MS), human immunodeficiency virus (HIV), adrenomyeloneuropathy (AMN) and pain, announced today that it has applied for an Orphan Drug designation from the U.S.-FDA for the Company's RPI-78M drug candidate for the treatment of myasthenia gravis (MG). In September 2015, Nutra Pharma was granted an Orphan Designation for this drug candidate for the treatment of pediatric MS. “We have been clear over the last year that we would be moving our drug platforms forward," stated…

MondayDec 07, 2015 12:10 am

Nutra Pharma Corp. (NPHC) is “One to Watch”

Nutra Pharma Corp. is a biotech company working in collaboration with its subsidiaries to develop an innovative pipeline of biopharmaceutical products for the management of neurological disorders, cancer, autoimmune, and infectious diseases. At the core of Nutra Pharma's intellectual property is a unique platform for extracting neurotoxins from Asian cobra venom and transforming them into non-toxic therapeutics. The ReceptoPharm subsidiary, Nutra Pharm's drug discovery arm, is focused on the development of new therapeutic agents based upon specialized receptor-binding proteins found in nature, especially those found in snake venom from the cobra. ReceptoPharm's R&D pipeline consists of several novel therapies in…

Site Search

Company Search

Tag: Nutra Pharma Corp. NPHC